Background Three drug classes (mineralocorticoid receptor antagonists [MRAs], angiotensin
receptor–neprilysin inhibitors [ARNIs], and sodium/glucose cotransporter 2 [SGLT2] …

Pharmacotherapies, including angiotensin-converting enzyme inhibitors (ACEIs),
angiotensin receptor II blockers (ARBs), β-blockers (BBs), mineralocorticoid receptor …

Heart failure (HF) prevalence remains high worldwide with significant sex-related and
regional differences in its presentation, management, and outcomes. In 2020, advances in …

Hypertension constitutes a major risk factor for heart failure with preserved ejection fraction
(HFpEF). HFpEF is a prevalent clinical syndrome with increased cardiovascular morbidity …

Mineralocorticoid receptor antagonists (MRAs), the angiotensin-receptor neprilysin inhibitor
(ARNI) sacubitril/valsartan, and sodium glucose cotransporter-2 inhibitors (SGLT2is) extend …

Importance The US Food and Drug Administration (FDA) expanded labeling for
sacubitril/valsartan for use in individuals with chronic heart failure (HF) with left ventricular …

Aims We investigated long‐term mortality associated with changes in left ventricular ejection
fraction (LVEF) in a large, real‐world patient cohort. Methods and results A total of 117 275 …

Heart failure is a clinical syndrome caused by ventricular insufficiency, which results in
decreased activity tolerance and repeated hospitalization, seriously affecting quality of life …

Aims To determine the efficacy of dietary interventions in Heart Failure with preserved
Ejection Fraction (HFpEF). Method and results Keyword searches were performed in five …

Aims We sought to determine sex‐based differences in biomarkers, self‐reported health
status, and magnitude of longitudinal changes in measures of reverse cardiac remodelling …